|Year : 2017 | Volume
| Issue : 1 | Page : 7-11
A practical and pyrogen-free preparation of 11C-L-methionine in a good manufacturing practice-compliant approach
Kang-Po Li1, Ming-Kuan Hu2, Cheng-Yi Cheng3, Li-Fan Hsu1, Ta-Kai Chou3, Chyng-Yann Shiue4, Daniel H Shen3
1 Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, China
2 School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, China
3 Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, China
4 PET Center, National Taiwan University Hospital, Taipei, Taiwan, China
|Date of Submission||13-Jun-2016|
|Date of Decision||01-Aug-2016|
|Date of Acceptance||22-Nov-2016|
|Date of Web Publication||22-Feb-2017|
Daniel H Shen
No. 325, Section 2, Chenggong Road, Neihu District, Taipei City 114, Taiwan
Source of Support: None, Conflict of Interest: None
Aims: 11C-L-methionine, an amino acid tracer used to delineate certain tumor tissues, has proven to be a prevailing nonfluorodeoxyglucose positron emission tomography (PET) radiopharmaceutical. We intended to prepare 11C-L-methionine by following modified synthetic strategies at a rebuilt working area to meet the PET drug current good manufacturing practice (cGMP) and Pharmaceutical Inspection Co-operation Scheme (PIC/S) regulations. Furthermore, we overcame the problem of pyrogen cross-contamination using a cleaner and more efficient program. Material and Methods: The task of upgrading air filtration equipment was integrated with the set of Web-Based Building Automation system (WebCTRL®). 11C-L-methionine synthesis was carried out in accordance with redesigned methods to meet the requirements of PET drug cGMP. The product quality was tested by a series of quality control tests and was found to be satisfactory. Depyrogenation was carried out by three different methods with different flow rates and flushing durations. The results were examined through limulus amebocyte lysate clotting test. Results: The level of air cleanliness in each section meets the PIC/S GMP standards after the reconstructions. Moreover, after delicate modifications, the radiochemical yield of 11C-L-methionine was 36.20% ± 3.59% (based on 11C-CH3I, n = 7), which is about 10% higher than the average former yield. Besides, the used depyrogenation methods could wipe the bioburden off within 8 h. Conclusions: The modifications done not only offer a good production environment but also protect the products from contamination. The modified approaches in both 11C-L-methionine production and depyrogenation resulted in prominent progress in stability and efficiency as well.
Keywords: Positron emission tomography, 11C-L-methionine, depyrogenation, good manufacturing practice
|How to cite this article:|
Li KP, Hu MK, Cheng CY, Hsu LF, Chou TK, Shiue CY, Shen DH. A practical and pyrogen-free preparation of 11C-L-methionine in a good manufacturing practice-compliant approach. J Med Sci 2017;37:7-11
|How to cite this URL:|
Li KP, Hu MK, Cheng CY, Hsu LF, Chou TK, Shiue CY, Shen DH. A practical and pyrogen-free preparation of 11C-L-methionine in a good manufacturing practice-compliant approach. J Med Sci [serial online] 2017 [cited 2018 Aug 18];37:7-11. Available from: http://www.jmedscindmc.com/text.asp?2017/37/1/7/200735
| Introduction|| |
11C-L-Methionine is used clinically in positron emission tomography (PET), detection of brain tumors,1 and imaging several malignancies.2-5 The default method of 11C-L-methionine synthesis is complicated, and some of the reagents are highly sensitive and easily degraded. Furthermore, some of the steps are not compliant with the quality assurance (QA) requirements of PET drug current good manufacturing practice (cGMP)., With respect to the aseptic issues, the old program could not guarantee a thoroughly sterile production system. Hence, in this study, we synthesized 11C-L-methionine by a modified protocol designed to overcome these obstacles.
| Materials and Methods|| |
Reconstruction of the working area and the cleanliness test
To meet the requirements of Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP, we redesigned our working area [Figure 1] and divided it into eight isolated sections. Then, we updated the air handling units, components of air circulation, high-efficiency particulate arrestance (HEPA) filters, and the sensors that were controlled by the central control system. The Web-Based Building Automation system (WebCTRL ®) was built by automated logic corporation.
|Figure 1: The redesigned clean rooms and the personnel flow. The reconstructions featured clear separation between different work areas and resulted in routes designed according to the principles of good manufacturing practice to keep off the cross-contamination. Furthermore, we set the environmental sensors to monitor the temperature, humidity, and pressure in each section. Information was recorded by Web-Based Building Automation system (WebCTRL®)|
Click here to view
The validation processes
After finishing the rebuilding work, we performed the validation processes including airborne particle count test, airflow test, air pressure differential test, filter leakage test, temperature test, humidity test, and settle plate test. In accordance with the standard operating procedure, we did the annual maintenance tests 1–4 times regularly. In addition, our measurement devices (i.e., the particle counter and air speed meter) were qualified by third party companies or laboratories.
Reagents and apparatus
Reagents and solvents were purchased from Aldrich and used without further purification. High-performance liquid chromatography (HPLC) analyses (Waters Corporation) were carried out with both ultraviolet and radioactivity detectors.11C-L-methionine was synthesized with a GE TRACERlab C module, which is an automatic synthesizer used in the production of PET drugs for years.11C-CO2 was generated in an IBA cyclone 18/9 cyclotron through the 14 N (p, α)11C nuclear reaction. The synthesizer was operated according to the modified sequence based on the wet method.,,,,,, The quality control of 11C-L-methionine followed all testing items and procedures listed in the United States Pharmacopeia.15
Small commercial package reagents for single use
In the previous protocols, at the reduction reaction step, we had to dilute high concentrations of lithium aluminum hydride (LiAlH4) in tetrahydrofuran (THF) solution to meet our requirements. This step was time-consuming, and the quality of the diluted solution was not always consistent. To improve the production stability, the procedure was delicately modified to include adding a small volume (0.5 M, 1 mL) of the commercial package of LiAlH4 from ABX into the reaction vessel before transferring the 11C-CO2.
Changes in iodination step
The default configurations of triphenylphosphine diiodide (Ph 3 PI2) and silver trifluoromethanesulfonate (AgOTf) solid-phase extraction (SPE) cartridges were cancelled and 57% hydriodic acid solution was used to accomplish this step instead. After the 11C-CO2 was transferred to 11C-CH3 OH through the modified reduction reaction procedure, the reaction vessel was heated to 160°C, and 0.5 mL of hydriodic acid was added to form the 11C-methyl iodide (11C-CH3I). The modified method for the production of 11C-methionine based on GE TRACERlab C module is illustrated in [Scheme 1]. The reaction steps are described briefly below:
- After the bombardment,11C-CO2 was reduced in the reaction vessel by a solution of LiAlH4 in THF (0.4 mL, 0.1 M)
- Hydriodic acid (0.5 mL) was added to the reaction vessel to form 11C-CH3I
- Five milligrams of L-homocysteine thiolactone. HCl in 0.4 mL of 0.3 M sodium hydroxide reacted with 11C-CH3I to yield 11C-methionine
- The crude product was purified by a semi-preparative HPLC system and passed through a 0.22-µm filter for further injection purposes.
HPLC contamination is always a troublesome laboratory issue, and the cleanup procedure is time-consuming. To find an easy and efficient way to wipe off the bioburden, we examined three approaches (methods A, B, and C) with different flow rates and flushing durations, using common reagents (75% ethanol, water, and acetic acid), and checked the results using limulus amebocyte lysate (LAL) clotting test. In these approaches, we used certified standard endotoxin as the positive control (pyrogen-contaminated sample) and LAL reagent water as the negative control.
| Results|| |
The improvement of the level of air cleanliness
After reconstructing our working area, it totally had eight chambers: anteroom 1, buffer room 1, buffer zone, anteroom 2, buffer room 2, manufacturing area, aseptic preparation area, and aseptic preparation area in isolator. Each room was equipped with independent HEPA filters and sensors that could send environmental parameters back to the WebCTRL ®. In addition, the improved monitoring functions of the new control system provided instant automated warnings if any abnormality occurred [Figure 2]. As shown in [Table 1], the data obtained from particle counting demonstrate that the level of air cleanliness in each section meets the PIC/S GMP standards.
|Figure 2: Air filtration and management systems (WebCTRL®) at our facility. Through the monitor, we could have good control of all environmental factors and get alerts instantly if any equipment goes wrong. Besides, all information would be recorded in the database for further analysis|
Click here to view
|Table 1: Comparison between the level of air cleanliness at our facility and the requirements of Pharmaceutical Inspection Co-operation Scheme good manufacturing practice|
Click here to view
The optimization of 11C-L-methionine-automated synthesis
The radiochemical yield of 11C-L-methionine was improved by the modified protocol to 36.20% ±3.59%, which is higher than the former yield by about 10% (n > 20). In addition, the radiochemical purity and specific activity reached 99.68% and 1510.85 Ci/mmol (based on 11C-CH3I, n = 7), respectively, in a relatively short synthetic time of 20 min from end of bombardment. Therefore, we optimized the automated synthetic procedure and furnished a higher yield and a more stable product through these improvements.
We examined three different procedures in the depyrogenation step and found that the three procedures worked well as all the final samples passed the LAL clotting test. Surprisingly, we found that method C could efficiently eliminate the bioburden within 8 h. The detailed methods are described in [Table 2].
| Discussion|| |
Good manufacturing practice-compliant environment
Our facility, built in 1992, has been offering good clinical care to patients for over 10 years. However, the performance of old air filtration equipment diminished gradually despite on-time maintenance. In addition, the flows of material and personnel were not organized. In our new requirements, the materials' flow is allowed only in one direction. The order is Zone 8, Zone 9, passing box, Zone 6, Zone 7, passing box, and finally the injection room. The same order applies for the personnel flow. The paths joining Zone 6 and Zone 7 are unidirectional as well. All staffs need to change their clothes to the first cleanroom suit at Zone 1. Furthermore, the staffs responsible for drug dispensing at Zone 7 need to wear the second cleanroom suit at Zone 4. These rules ensure a high level of air cleanliness and effectively avoid cross-contamination (Zone 7 exhibits the highest level of air cleanliness). Moreover, the set of WebCTRL that integrates all environmental information (temperature, humidity, pressure, and conditions of supplied air) made the management easier to control. All these factors could ensure a high-quality manufacturing environment in our facility.
Modified method of 11C-L-methionine synthesis
According to the original instructions given by the provider, some reagents used in 11C-L-methionine preparation should be treated before being loaded in the synthesizer, such as Ph 3 PI2 on Al2O3 and AgOTf cartridges that were used to produce 11C-Met and 11C-MeOTf, followed by coupling with the precursor to afford the crude 11C-L-methionine. Nevertheless, those two materials were extremely sensitive and highly susceptible to degradation while preparing the SPE cartridges (weighing it, filling it in the cartridge, and sealing the cartridge). Thus, the qualities of those materials were not consistent among the steps of the synthesis and completely depended on the handling skills of the personnel. This does not agree with the principles of QA. To overcome this problem, we developed and reschemed the protocols, using 57% hydriodic acid as the iodination reagent to convert 11C-CH3 OH to 11C-CH3I (commercialized package, directly added in reaction vessel without further process). The commercially available hydriodic acid has packed in a light-protective bottle and stored at 2–8°C. Both hydriodic acid and LiAlH4 (0.5 M in THF, 1 mL) were purchased from ABX for single use to assure their quality. More importantly, LiAlH4/THF must be loaded to the reaction vessel only after purging the vessel with helium gas. Eventually, the yield of the final product increased by 10%, and the average standard deviation decreased by 6.5% in comparison with the previous results. In addition, the stability of the products was improved. The comparison between the default and selected reaction reagents is shown in [Table 3].
|Table 3: Comparison between the synthetic agents utilized in the default and modified methods of 11C-methionine production|
Click here to view
New depyrogenation method
Pyrogen contamination is a tedious problem in radiopharmaceutical production. Although there are several methods proposed to address this problem, it is still difficult to be solved in a quick and effective way. Our experience showed that 0.1–1.0 M sodium hydroxide solution could be used to avoid pyrogen contamination. Nonetheless, this method was not suitable due to the low tolerance to high pH in the reverse phase column (VP 250/16 NUCLEOSIL 100-7 C18). Several trials were done using 1% acetic acid solution to cope with this issue. Finally, method C was found to be the best procedure to accomplish the preparation of 11C-L-methionine without pyrogen contamination. Not only did it solve the pyrogen contamination problem but also it completed the whole depyrogenation procedure within 8 h, which demonstrates how this approach is timesaving.
| Conclusions|| |
The modifications in production environment not only provide a GMP compliant manufacturing areas to produce the guaranteed clinical radiopharmaceuticals but also improve the level of air cleanliness. The modified approaches guarantee a stable production of PET drugs and offer an efficient way to prominently remove the possible pyrogen contaminations.
Financial support and sponsorship
The work was supported by grants from Tri-Service General Hospital and National Defense Medical Center.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, et al.
Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med 2012;37:158-63.
Fukuda H, Kubota K, Matsuzawa T. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology. Tohoku J Exp Med 2013;230:155-69.
Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al.
Value of 11
C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 2013;40:615-35.
Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y, et al.
Evaluation of brain tumors using dynamic 11
C-methionine-PET. J Neurooncol 2012;109:115-22.
Gulyás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging 2012;56:173-90.
Lodi F, Malizia C, Castellucci P, Cicoria G, Fanti S, Boschi S. Synthesis of oncological 11
C radiopharmaceuticals for clinical PET. Nucl Med Biol 2012;39:447-60.
Comar D, Cartron J, Maziere M, Marazano C. Labelling and metabolism of methionine-methyl-11
C. Eur J Nucl Med 1976;1:11-4.
Långström B, Lundqvist H. The preparation of 11
C-methyl iodide and its use in the synthesis of 11
C-methyl-L-methionine. Int J Appl Radiat Isot 1976;27:357-63.
Davis J, Yano Y, Cahoon J, Budinger TF. Preparation of 11
C-methyl iodide and L-[S-methyl-11
C] methionine by an automated continuous flow process. Int J Appl Radiat Isot 1982;33:363-9.
Långström B, Antoni G, Gullberg P, Halldin C, Malmborg P, Någren K, et al.
Synthesis of L- and D-[methyl-11
C] methionine. J Nucl Med 1987;28:1037-40.
Kniess T, Rode K, Wuest F. Practical experiences with the synthesis of [11
I through gas phase iodination reaction using a TRACERlabFXC synthesis module. Appl Radiat Isot 2008;66:482-8.
Gómez-Vallejo V, Llop J. Specific activity of [11
I synthesized by the “wet” method: Main sources of non-radioactive carbon. Appl Radiat Isot 2009;67:111-4.
Methionine C 11 injection. United States Pharmacopeia 2014 U.S. Pharmacopoeia-National Formulary [USP 37 NF 32]. Vol. 2. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2014. p. 2140-1.
Ronald EM. The cleaning and regeneration of reversed-phase HPLC columns. LCGC Europe 2003:2-6.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3]